Overview

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Phase:
PHASE3
Details
Lead Sponsor:
Neurocrine Biosciences